ClearPoint Neuro (CLPT) director settles 12,417 RSUs into common stock

Rhea-AI Filing Summary

ClearPoint Neuro director Kristine B. Johnson exercised and settled 12,417 restricted stock units into an equal number of common shares on May 19, 2026. These RSUs were granted on May 22, 2025 and vested on their scheduled vesting date. After the settlement, she directly holds 71,116 shares of ClearPoint Neuro common stock.

Insider Trade Summary

12,417 shares exercised/converted

Mixed 2 txns

Insider JOHNSON B KRISTINE

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	--
Exercise	Common Stock	12,417	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Common Stock — 71,116 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs settled: 12,417 units Shares received: 12,417 shares Post-transaction holdings: 71,116 shares +1 more

4 metrics

RSUs settled 12,417 units Restricted stock units converted to common stock on May 19, 2026

Shares received 12,417 shares Common stock issued upon RSU settlement

Post-transaction holdings 71,116 shares Common stock directly held by Kristine B. Johnson after settlement

RSU grant date May 22, 2025 Grant date for 12,417 restricted stock units

Key Terms

Restricted Stock Units, derivative security, vesting date

3 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date, reported with a derivative security code."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting date financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON B KRISTINE

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		12,417	A	(1)	71,116	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/19/2026		M			12,417	(1)	(1)	Common Stock	12,417	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for B. Kristine Johnson	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Kristine B. Johnson?

ClearPoint Neuro reported that director Kristine B. Johnson settled 12,417 restricted stock units into the same number of common shares. This was a scheduled equity compensation event rather than an open-market purchase or sale, and reflects routine conversion of previously granted RSUs.

How many ClearPoint Neuro (CLPT) shares does Kristine B. Johnson hold after this Form 4?

After the reported transaction, Kristine B. Johnson directly holds 71,116 shares of ClearPoint Neuro common stock. This total reflects the addition of 12,417 shares received from settling vested restricted stock units granted as part of her director compensation program.

Was the ClearPoint Neuro (CLPT) Form 4 a stock purchase or sale?

The Form 4 shows neither an open-market purchase nor a sale. Instead, it reports the exercise and settlement of 12,417 restricted stock units into common stock, a non-cash equity compensation event occurring on the scheduled vesting date of those RSUs.

What were the terms of the 12,417 restricted stock units at ClearPoint Neuro (CLPT)?

The 12,417 restricted stock units were granted on May 22, 2025, each representing a right to receive one share of ClearPoint Neuro common stock. They vested on the earlier of the first anniversary of the grant date or the day before the company’s 2026 annual stockholder meeting.

Does the ClearPoint Neuro (CLPT) Form 4 indicate any remaining derivative or RSU holdings?

The Form 4 indicates that after settlement, the reported block of 12,417 restricted stock units has a remaining balance of zero. The derivative summary in this filing does not list additional outstanding derivative positions, focusing solely on this vesting and settlement event.